KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 126 filers reported holding KALA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $22,000 | -80.9% | 18,040 | -59.0% | 0.01% | -80.5% |
| Q3 2021 | $115,000 | -49.6% | 43,990 | +2.3% | 0.04% | -48.8% |
| Q2 2021 | $228,000 | -10.6% | 42,990 | +13.8% | 0.08% | -14.0% |
| Q1 2021 | $255,000 | +46.6% | 37,790 | +47.4% | 0.09% | +38.8% |
| Q4 2020 | $174,000 | +68.9% | 25,640 | +86.2% | 0.07% | +42.6% |
| Q3 2020 | $103,000 | – | 13,770 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |